The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients
BACKGROUND:Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infected patients is unknown. METHODS:We evaluated the impact of NFV on cancer development in a large cohor...
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2009-07, Vol.51 (3), p.305-309 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 309 |
|---|---|
| container_issue | 3 |
| container_start_page | 305 |
| container_title | Journal of acquired immune deficiency syndromes (1999) |
| container_volume | 51 |
| creator | Crum-Cianflone, Nancy F Hullsiek, Katherine Huppler Marconi, Vincent Weintrob, Amy Ganesan, Anuradha Barthel, R Vincent Fraser, Susan Roediger, Mollie Poehlman Agan, Brian Wegner, Scott |
| description | BACKGROUND:Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infected patients is unknown.
METHODS:We evaluated the impact of NFV on cancer development in a large cohort of HIV-infected persons with 108 cancer events during 13,421 person-years of follow-up. Using multivariate time-updated Cox proportional hazard models, the risk of cancer among those receiving NFV were compared to those on non-NFV antiretroviral regimens.
RESULTS:The risk of cancer among those receiving NFV was similar to those on non-NFV antiretroviral regimens (hazard ratio 1.0, 95% confidence interval 0.5, 1.7, P = 0.90). We also examined AIDS-defining and non-AIDS-defining cancers separately and found no significant associations between NFV use and cancer risk. Antiretroviral use, with or without a protease inhibitor (PI) component, was associated with a reduced risk of AIDS-defining cancers compared with no antiretroviral therapy; however, the risk of cancer was the same among those using PI or PI-sparing regimens.
DISCUSSION:Despite reports that NFV may have tumoricidal activity, we found no significant relationship between NFV or PI use compared with other antiretrovirals and the risk of developing cancer among a large cohort of HIV-infected persons. |
| doi_str_mv | 10.1097/QAI.0b013e3181aa13c7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2720269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67414255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6107-b61fc3932b388068f7cf75edec743b1377ef5154d1c1377ccff029bd9f0d551c3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEomXhHyBkIQGnFE_s2Mml0mopNNKKD6lwtRxnvJuSxMFOtvDv8bKrAj30NLb8zOuxnyR5DvQMaCnffllWZ7SmwJBBAVoDM_JBcgol56ksCv4wrvMsTzmw_CR5EsI1pSA4Lx8nJxGCDECcJni1RVL1ozYTcZZ8xM62g961nlz8HF2YPRI3kJUeDHryDnfYubHHYSLL3g0bosla-w2Slds6_yfhsvqWVoNFM2FDPuupjXB4mjyyugv47FgXydf3F1ery3T96UO1Wq5TI4DKtBZgDStZVrOioKKw0liZY4NGclYDkxJtDjlvwOw3xlhLs7JuSkubPAfDFsn5IXec6x4bE-_2ulOjb3vtfymnW_X_ydBu1cbtVCYzmokyBrw5Bnj3Y8Ywqb4NBrtOD-jmoCQXFHhR7snX95JCcuBZnkfw5R3w2s1-iN-gMsaEEEUsi4QfIONdCB7t7cxA1V63irrVXd2x7cW_7_3bdPQbgVdHQAejO-ujyDbcchkIKWQBkSsO3I3rJvThezffoFdb1N20vX-G34U0xhA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>233666823</pqid></control><display><type>article</type><title>The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Free E- Journals</source><source>Journals@Ovid Complete</source><creator>Crum-Cianflone, Nancy F ; Hullsiek, Katherine Huppler ; Marconi, Vincent ; Weintrob, Amy ; Ganesan, Anuradha ; Barthel, R Vincent ; Fraser, Susan ; Roediger, Mollie Poehlman ; Agan, Brian ; Wegner, Scott</creator><creatorcontrib>Crum-Cianflone, Nancy F ; Hullsiek, Katherine Huppler ; Marconi, Vincent ; Weintrob, Amy ; Ganesan, Anuradha ; Barthel, R Vincent ; Fraser, Susan ; Roediger, Mollie Poehlman ; Agan, Brian ; Wegner, Scott</creatorcontrib><description>BACKGROUND:Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infected patients is unknown.
METHODS:We evaluated the impact of NFV on cancer development in a large cohort of HIV-infected persons with 108 cancer events during 13,421 person-years of follow-up. Using multivariate time-updated Cox proportional hazard models, the risk of cancer among those receiving NFV were compared to those on non-NFV antiretroviral regimens.
RESULTS:The risk of cancer among those receiving NFV was similar to those on non-NFV antiretroviral regimens (hazard ratio 1.0, 95% confidence interval 0.5, 1.7, P = 0.90). We also examined AIDS-defining and non-AIDS-defining cancers separately and found no significant associations between NFV use and cancer risk. Antiretroviral use, with or without a protease inhibitor (PI) component, was associated with a reduced risk of AIDS-defining cancers compared with no antiretroviral therapy; however, the risk of cancer was the same among those using PI or PI-sparing regimens.
DISCUSSION:Despite reports that NFV may have tumoricidal activity, we found no significant relationship between NFV or PI use compared with other antiretrovirals and the risk of developing cancer among a large cohort of HIV-infected persons.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/QAI.0b013e3181aa13c7</identifier><identifier>PMID: 19412116</identifier><identifier>CODEN: JDSRET</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adult ; Anticarcinogenic Agents - administration & dosage ; Antiretroviral drugs ; Antiretroviral Therapy, Highly Active ; Biological and medical sciences ; Cancer ; Cohort Studies ; Comparative analysis ; Female ; Fundamental and applied biological sciences. Psychology ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV Protease Inhibitors - administration & dosage ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Male ; Medical sciences ; Microbiology ; Miscellaneous ; Nelfinavir - administration & dosage ; Neoplasms - epidemiology ; Neoplasms - etiology ; Neoplasms - prevention & control ; Proportional Hazards Models ; Retrospective Studies ; Risk ; Risk factors ; Tumors ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virology</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2009-07, Vol.51 (3), p.305-309</ispartof><rights>2009 Lippincott Williams & Wilkins, Inc.</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Jul 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6107-b61fc3932b388068f7cf75edec743b1377ef5154d1c1377ccff029bd9f0d551c3</citedby><cites>FETCH-LOGICAL-c6107-b61fc3932b388068f7cf75edec743b1377ef5154d1c1377ccff029bd9f0d551c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21676781$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19412116$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crum-Cianflone, Nancy F</creatorcontrib><creatorcontrib>Hullsiek, Katherine Huppler</creatorcontrib><creatorcontrib>Marconi, Vincent</creatorcontrib><creatorcontrib>Weintrob, Amy</creatorcontrib><creatorcontrib>Ganesan, Anuradha</creatorcontrib><creatorcontrib>Barthel, R Vincent</creatorcontrib><creatorcontrib>Fraser, Susan</creatorcontrib><creatorcontrib>Roediger, Mollie Poehlman</creatorcontrib><creatorcontrib>Agan, Brian</creatorcontrib><creatorcontrib>Wegner, Scott</creatorcontrib><title>The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>BACKGROUND:Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infected patients is unknown.
METHODS:We evaluated the impact of NFV on cancer development in a large cohort of HIV-infected persons with 108 cancer events during 13,421 person-years of follow-up. Using multivariate time-updated Cox proportional hazard models, the risk of cancer among those receiving NFV were compared to those on non-NFV antiretroviral regimens.
RESULTS:The risk of cancer among those receiving NFV was similar to those on non-NFV antiretroviral regimens (hazard ratio 1.0, 95% confidence interval 0.5, 1.7, P = 0.90). We also examined AIDS-defining and non-AIDS-defining cancers separately and found no significant associations between NFV use and cancer risk. Antiretroviral use, with or without a protease inhibitor (PI) component, was associated with a reduced risk of AIDS-defining cancers compared with no antiretroviral therapy; however, the risk of cancer was the same among those using PI or PI-sparing regimens.
DISCUSSION:Despite reports that NFV may have tumoricidal activity, we found no significant relationship between NFV or PI use compared with other antiretrovirals and the risk of developing cancer among a large cohort of HIV-infected persons.</description><subject>Adult</subject><subject>Anticarcinogenic Agents - administration & dosage</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Cohort Studies</subject><subject>Comparative analysis</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Protease Inhibitors - administration & dosage</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Nelfinavir - administration & dosage</subject><subject>Neoplasms - epidemiology</subject><subject>Neoplasms - etiology</subject><subject>Neoplasms - prevention & control</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Risk factors</subject><subject>Tumors</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Virology</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhiMEomXhHyBkIQGnFE_s2Mml0mopNNKKD6lwtRxnvJuSxMFOtvDv8bKrAj30NLb8zOuxnyR5DvQMaCnffllWZ7SmwJBBAVoDM_JBcgol56ksCv4wrvMsTzmw_CR5EsI1pSA4Lx8nJxGCDECcJni1RVL1ozYTcZZ8xM62g961nlz8HF2YPRI3kJUeDHryDnfYubHHYSLL3g0bosla-w2Slds6_yfhsvqWVoNFM2FDPuupjXB4mjyyugv47FgXydf3F1ery3T96UO1Wq5TI4DKtBZgDStZVrOioKKw0liZY4NGclYDkxJtDjlvwOw3xlhLs7JuSkubPAfDFsn5IXec6x4bE-_2ulOjb3vtfymnW_X_ydBu1cbtVCYzmokyBrw5Bnj3Y8Ywqb4NBrtOD-jmoCQXFHhR7snX95JCcuBZnkfw5R3w2s1-iN-gMsaEEEUsi4QfIONdCB7t7cxA1V63irrVXd2x7cW_7_3bdPQbgVdHQAejO-ujyDbcchkIKWQBkSsO3I3rJvThezffoFdb1N20vX-G34U0xhA</recordid><startdate>200907</startdate><enddate>200907</enddate><creator>Crum-Cianflone, Nancy F</creator><creator>Hullsiek, Katherine Huppler</creator><creator>Marconi, Vincent</creator><creator>Weintrob, Amy</creator><creator>Ganesan, Anuradha</creator><creator>Barthel, R Vincent</creator><creator>Fraser, Susan</creator><creator>Roediger, Mollie Poehlman</creator><creator>Agan, Brian</creator><creator>Wegner, Scott</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200907</creationdate><title>The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients</title><author>Crum-Cianflone, Nancy F ; Hullsiek, Katherine Huppler ; Marconi, Vincent ; Weintrob, Amy ; Ganesan, Anuradha ; Barthel, R Vincent ; Fraser, Susan ; Roediger, Mollie Poehlman ; Agan, Brian ; Wegner, Scott</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6107-b61fc3932b388068f7cf75edec743b1377ef5154d1c1377ccff029bd9f0d551c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Anticarcinogenic Agents - administration & dosage</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Cohort Studies</topic><topic>Comparative analysis</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Protease Inhibitors - administration & dosage</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Nelfinavir - administration & dosage</topic><topic>Neoplasms - epidemiology</topic><topic>Neoplasms - etiology</topic><topic>Neoplasms - prevention & control</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Risk factors</topic><topic>Tumors</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crum-Cianflone, Nancy F</creatorcontrib><creatorcontrib>Hullsiek, Katherine Huppler</creatorcontrib><creatorcontrib>Marconi, Vincent</creatorcontrib><creatorcontrib>Weintrob, Amy</creatorcontrib><creatorcontrib>Ganesan, Anuradha</creatorcontrib><creatorcontrib>Barthel, R Vincent</creatorcontrib><creatorcontrib>Fraser, Susan</creatorcontrib><creatorcontrib>Roediger, Mollie Poehlman</creatorcontrib><creatorcontrib>Agan, Brian</creatorcontrib><creatorcontrib>Wegner, Scott</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crum-Cianflone, Nancy F</au><au>Hullsiek, Katherine Huppler</au><au>Marconi, Vincent</au><au>Weintrob, Amy</au><au>Ganesan, Anuradha</au><au>Barthel, R Vincent</au><au>Fraser, Susan</au><au>Roediger, Mollie Poehlman</au><au>Agan, Brian</au><au>Wegner, Scott</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2009-07</date><risdate>2009</risdate><volume>51</volume><issue>3</issue><spage>305</spage><epage>309</epage><pages>305-309</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><coden>JDSRET</coden><abstract>BACKGROUND:Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infected patients is unknown.
METHODS:We evaluated the impact of NFV on cancer development in a large cohort of HIV-infected persons with 108 cancer events during 13,421 person-years of follow-up. Using multivariate time-updated Cox proportional hazard models, the risk of cancer among those receiving NFV were compared to those on non-NFV antiretroviral regimens.
RESULTS:The risk of cancer among those receiving NFV was similar to those on non-NFV antiretroviral regimens (hazard ratio 1.0, 95% confidence interval 0.5, 1.7, P = 0.90). We also examined AIDS-defining and non-AIDS-defining cancers separately and found no significant associations between NFV use and cancer risk. Antiretroviral use, with or without a protease inhibitor (PI) component, was associated with a reduced risk of AIDS-defining cancers compared with no antiretroviral therapy; however, the risk of cancer was the same among those using PI or PI-sparing regimens.
DISCUSSION:Despite reports that NFV may have tumoricidal activity, we found no significant relationship between NFV or PI use compared with other antiretrovirals and the risk of developing cancer among a large cohort of HIV-infected persons.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>19412116</pmid><doi>10.1097/QAI.0b013e3181aa13c7</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-4135 |
| ispartof | Journal of acquired immune deficiency syndromes (1999), 2009-07, Vol.51 (3), p.305-309 |
| issn | 1525-4135 1944-7884 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2720269 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Free E- Journals; Journals@Ovid Complete |
| subjects | Adult Anticarcinogenic Agents - administration & dosage Antiretroviral drugs Antiretroviral Therapy, Highly Active Biological and medical sciences Cancer Cohort Studies Comparative analysis Female Fundamental and applied biological sciences. Psychology HIV HIV Infections - complications HIV Infections - drug therapy HIV Protease Inhibitors - administration & dosage Human immunodeficiency virus Human viral diseases Humans Infectious diseases Male Medical sciences Microbiology Miscellaneous Nelfinavir - administration & dosage Neoplasms - epidemiology Neoplasms - etiology Neoplasms - prevention & control Proportional Hazards Models Retrospective Studies Risk Risk factors Tumors Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Virology |
| title | The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T05%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Nelfinavir%20Exposure%20on%20Cancer%20Development%20Among%20a%20Large%20Cohort%20of%20HIV-Infected%20Patients&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Crum-Cianflone,%20Nancy%20F&rft.date=2009-07&rft.volume=51&rft.issue=3&rft.spage=305&rft.epage=309&rft.pages=305-309&rft.issn=1525-4135&rft.eissn=1944-7884&rft.coden=JDSRET&rft_id=info:doi/10.1097/QAI.0b013e3181aa13c7&rft_dat=%3Cproquest_pubme%3E67414255%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=233666823&rft_id=info:pmid/19412116&rfr_iscdi=true |